Health Care · Biological Products, (No Diagnostic Substances)

ATYR aTYR PHARMA INC SEC Filings & Insider Trading Activity 2026

company
CIK 1339970100 filings
Russell 2000

ATYR at a glance

aTYR PHARMA INC (ATYR, SEC CIK 1339970) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80.
  • As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding aTYR PHARMA INC (ATYR) shares worth $2.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by SCHIMMEL PAUL on May 27, 2026 of 100,000 shares at $0.50 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$190K
−19.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
16 funds
$2.9M · −3 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added regulatory risk: FDA viewed EFZO-FIT as failed, with the Proposed Phase 3 Study potentially insufficient for approval
  • Most material operational change: CDMO received a March 2026 Form 483 and plans microbial-site relocation, threatening future manufacturing continuity
  • Most impactful financial risk: $50.3 million available liquidity, with additional capital needed for later clinical development and commercialization
  • Near-term execution risk: Proposed Phase 3 Study activities expected in fourth quarter 2026, but advancement depends on securing a strategic partner
  • Workforce risk: August 2026 restructuring reduced total employees by approximately 60% to 20 full-time employees

Management Discussion & Analysis

  • Revenue $0, down $190,000 YoY from license and collaboration agreement revenue
  • R&D expenses $10.4M vs $22.1M YoY, down $11.7M
  • Worst performer: efzofitimod expenses $1.5M vs $18.8M, down $17.2M
  • Cash, equivalents, restricted cash and investments $50.3M; operating cash used $31.4M
  • Near-term outlook: lower expenses after restructuring and strategic-partnership prioritization, with capital needs remaining beyond one year

AI summary of the ATYR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 8.01: Other Events

  • Nasdaq minimum bid-price compliance restored after shares closed at least $1.00 for 10 consecutive business days
  • Compliance period ran October 30 through November 12, 2026
Filed Nov 6, 2026Full analysis →

Item 8.01: Other Events

  • ATM equity offering of up to $79,994,251 through Jefferies under the existing Sales Agreement
  • Potential share issuance creates dilution risk for existing ATYR shareholders
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers aTyr Pharma’s quarter ended September 30, 2026
  • Financial results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FDA-aligned Phase 3 efzofitimod protocol, using FVC as primary endpoint, moves pulmonary sarcoidosis program toward pivotal testing
  • Strategic partnerships or licensing now prioritized, creating execution and funding dependence on external financing or collaboration

AI summaries of ATYR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ATYR

Don't miss the next ATYR filing

  • Alerts as it files. A push when ATYR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ATYR, by share count.
  • Ask anything. An AI agent that reads every ATYR filing and answers with sources.

ATYR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Yaras BrandonAOct 1, 2026-
SCHIMMEL PAULBuyMay 27, 2026$0.50
Zaknoen SaraAMay 11, 2026-
Gross Jane AAMay 11, 2026-
BENEVICH ERICAMay 11, 2026-
SCHIMMEL PAULAMay 11, 2026-
Gross Jane AAMay 11, 2026-
Coughlin TimothyAMay 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$353K$235K$190K
Operating Income--$67.9M-$77.6M
Net Income-$50.4M-$64.0M-$74.1M
Op. Margin--28899.6%-40856.3%
Net Margin-14274.5%-27243.8%-39009.5%
Balance Sheet
Total Assets-$96.8M$93.0M
Equity$90.7M$70.0M$67.5M
ROE-55.6%-91.4%-109.8%
Per Share
EPS$-0.94$-0.86$-0.80
Cash Flow
Operating CF--$69.1M-$62.0M
CapEx-$65K$77K

Source: XBRL data in aTYR PHARMA INC (ATYR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ATYR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ATYR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202616$2.9M
Q2 202619$10.3M
Q1 202624$26.3M
Q4 202520$25.6M
Q3 202523$26.8M
Q2 202522$152.9M
Q1 202514$64.3M
Q4 202411$63.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 149 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ATYR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
10-QNov 6, 2026Analysis
8-KNov 6, 2026Analysis-
8-KNov 5, 2026Analysis-
8-KOct 27, 2026Analysis-
8-KOct 16, 2026Analysis-
4Oct 1, 2026--
8-KSep 24, 2026Analysis-
10-QAug 7, 2026Analysis
8-KAug 7, 2026Analysis-
8-KJul 31, 2026Analysis-
8-KJun 8, 2026Analysis
8-KJun 1, 2026Analysis
4May 28, 2026-
10-QMay 15, 2026Analysis
8-KMay 15, 2026Analysis
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
8-KMay 11, 2026Analysis
10-KMar 5, 2026-
8-KMar 5, 2026--
4Feb 4, 2026-

Related Health Care companies

All Health Care →

ATYR SEC filings: frequently asked questions

Which institutions hold ATYR stock?

As of September 30, 2026, the largest aTYR PHARMA INC (ATYR) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.1 million), BlackRock ($491,000), Morgan Stanley ($334,000), AQR Capital Management ($209,000), Millennium Management ($176,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ATYR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.

What did ATYR report in its latest 8-K?

aTYR PHARMA INC (ATYR) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). Nasdaq minimum bid-price compliance restored after shares closed at least $1.00 for 10 consecutive business days.

What are the latest ATYR SEC filings?

aTYR PHARMA INC (ATYR) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on October 1, 2026.

What is ATYR's SEC CIK number?

aTYR PHARMA INC (ATYR)'s SEC Central Index Key (CIK) is 1339970. EDGAR lists every ATYR filing under that number.

Ask anything about ATYR

The research agent reads ATYR's filings, financials, insider trades and 13F holders, then answers with sources.